U.S. Congress legislation · 119th Congress
HB10094: Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026
Status: In committee, August 13, 2026
To require persons who undertake federally funded research and development of a biomedical product or service to enter into reasonable pricing agreements with the Secretary of Health and Human Services, and for other purposes.
What the bill says
To require persons who undertake federally funded research and development of a biomedical product or service to enter into reasonable pricing agreements with the Secretary of Health and Human Services, and for other purposes.
From the introduced text, August 13, 2026:
A BILL To require persons who undertake federally funded research and development of a biomedical product or service to enter into reasonable pricing agreements with the Secretary of Health and Human Services, and for other purposes. SECTION 1. Short title This Act may be cited as the Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 . SECTION 2. Reasonable price agreement (a) In general All Federal agencies providing or receiving research funding, through a grant, contract, cooperative agreement, or other agreement, shall require in such agreement, and in any license of the rights to a patent or regulatory test data for a biomedical product or service, that the price of any biomedical product or service developed with the benefit of such research be reasonable (as determined by the Secretary) unless the Secretary waives such reasonable price obligation under subsection (d). (b) Prohibition against charging prices higher than in other large economies with high incomes (1) In general For purposes of subsection (a), any reasonable pricing formula shall ensure, without prejudice to any other standards or negotiated provisions for reasonable pricing, that residents of the United States are not charged more for the biomedical product or service involved than the reference price for countries with large economies and high incomes. (2) Reference price For purposes of paragraph (1), the phrase …
Sponsors
- Hoyle, Val T. (D) · primary sponsor
- Lloyd Doggett (D, HD-037)
- Melanie Stansbury (D)
- Mark Takano (D)
- Norton, Eleanor (D, HD-000)
- Rashida Tlaib (D, HD-MI-12)
- Pramila Jayapal (D, HD-007)
- Greg Casar (D, 35)
- Jill Tokuda (D, HD-002)
- Steve Cohen (D, HD-009)
- Ro Khanna (D)
- Jesus Garcia (D, HD-IL-4)
Latest actions
- : Referred to the House Committee on Energy and Commerce.
- : Introduced in House
Subjects: Health
Common questions
- What is HB10094?
- HB10094 is a bill in Congress (119th Congress): Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026.
- What does HB10094 do?
- In its own words: To require persons who undertake federally funded research and development of a biomedical product or service to enter into reasonable pricing agreements with the Secretary of Health and Human Services, and for other purposes.
- What is the status of HB10094?
- In committee as of August 13, 2026. Latest action: Referred to the House Committee on Energy and Commerce. (August 13, 2026).
- Who sponsored HB10094?
- Hoyle, Val T. (D), with 11 co-sponsors.
- Where is the official record for HB10094?
- On the Congress website: https://www.congress.gov/bill/119th-congress/house-bill/10094
Source: official Congress record. Tracked by Delilah, AI for legislation across all 50 states and Congress.